Taihua plc

("Taihua" or the "Company")

Renewal of Chinese Good Manufacturing Practice certificate

The Company confirms today that it has begun making preparations for the renewal of its Chinese Good Manufacturing Practice ("GMP") certificate.

Accordingly, all production of traditional Chinese medicines ("TCMs"), homoharringtonine and paclitaxel has ceased whilst the Company's production facilities are refitted to ensure compliance with the new GMP standards.

It is anticipated that the Company's facilities will be audited by the relevant authority and the new certificate will be granted before the end of 2015. The TCMs production will resume before 30 September 2015 after the audit as its existing GMP certificate expires on 31 December 2015 and the homoharringtonine and paclitaxel production will resume before the end of 2015 after Taihua obtains the renewed GMP certificate.

The Company does not anticipate that this will have any immediate effect on trading, as it has sufficient stock to fulfil all anticipated orders for these products over the next few months. In addition, the directors have no reason to believe that the GMP certificate will not be granted, but in the event it is not granted, the lack of the licence will mean that the Company will be unable to produce TCMs, homoharringtonine and paclitaxel going forward which would have a material impact on the Company.

ENDS

Enquiries:

Nicholas Lyth, Taihua plc                                                              07769 906 686

Katy Mitchell, WH Ireland Limited                                           +44 161 832 2174